Eyepoint Pharmaceuticals Stock Target Price
| EYPT Stock | USD 19.94 1.90 10.53% |
Eyepoint Pharmaceuticals fundamentals help investors to digest information that contributes to Eyepoint Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Eyepoint Stock. The fundamental analysis module provides a way to measure Eyepoint Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Eyepoint Pharmaceuticals stock.
Eyepoint | Target Price |
Eyepoint Target Price Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Eyepoint Pharmaceuticals' direct or indirect competition against its Target Price to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Eyepoint Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Eyepoint Pharmaceuticals by comparing valuation metrics of similar companies.Eyepoint Pharmaceuticals is currently under evaluation in target price category among related companies.
Eyepoint Fundamentals
| Return On Equity | -0.39 | ||||
| Return On Asset | -0.17 | ||||
| Profit Margin | (1.54) % | ||||
| Operating Margin | (1.08) % | ||||
| Current Valuation | 573.37 M | ||||
| Shares Outstanding | 52.08 M | ||||
| Shares Owned By Insiders | 0.98 % | ||||
| Shares Owned By Institutions | 99.02 % | ||||
| Number Of Shares Shorted | 6.54 M | ||||
| Price To Earning | (2.82) X | ||||
| Price To Book | 4.20 X | ||||
| Price To Sales | 24.31 X | ||||
| Revenue | 46.02 M | ||||
| Gross Profit | 26.95 M | ||||
| EBITDA | (73.2 M) | ||||
| Net Income | (70.8 M) | ||||
| Cash And Equivalents | 171.17 M | ||||
| Cash Per Share | 5.02 X | ||||
| Total Debt | 5.47 M | ||||
| Debt To Equity | 0.30 % | ||||
| Current Ratio | 6.16 X | ||||
| Book Value Per Share | 5.43 X | ||||
| Cash Flow From Operations | 1.88 M | ||||
| Short Ratio | 9.02 X | ||||
| Earnings Per Share | (1.82) X | ||||
| Target Price | 43.67 | ||||
| Number Of Employees | 121 | ||||
| Beta | 1.68 | ||||
| Market Capitalization | 939.6 M | ||||
| Total Asset | 355.18 M | ||||
| Retained Earnings | (742.15 M) | ||||
| Working Capital | 281.54 M | ||||
| Current Asset | 15.08 M | ||||
| Current Liabilities | 11.26 M | ||||
| Net Asset | 355.18 M |
About Eyepoint Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Eyepoint Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Eyepoint Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Eyepoint Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Eyepoint Pharmaceuticals
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Eyepoint Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Eyepoint Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.Moving together with Eyepoint Stock
| 0.63 | JNJ | Johnson Johnson Aggressive Push | PairCorr |
Moving against Eyepoint Stock
| 0.79 | GCTK | GlucoTrack | PairCorr |
| 0.79 | MPW | Medical Properties Trust Earnings Call This Week | PairCorr |
| 0.68 | DXR | Daxor | PairCorr |
The ability to find closely correlated positions to Eyepoint Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Eyepoint Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Eyepoint Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Eyepoint Pharmaceuticals to buy it.
The correlation of Eyepoint Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Eyepoint Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Eyepoint Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Eyepoint Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Eyepoint Pharmaceuticals Piotroski F Score and Eyepoint Pharmaceuticals Altman Z Score analysis. For more information on how to buy Eyepoint Stock please use our How to Invest in Eyepoint Pharmaceuticals guide.You can also try the Technical Analysis module to check basic technical indicators and analysis based on most latest market data.
Complementary Tools for Eyepoint Stock analysis
When running Eyepoint Pharmaceuticals' price analysis, check to measure Eyepoint Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Eyepoint Pharmaceuticals is operating at the current time. Most of Eyepoint Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Eyepoint Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Eyepoint Pharmaceuticals' price. Additionally, you may evaluate how the addition of Eyepoint Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins |
Is Eyepoint Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Eyepoint Pharmaceuticals. If investors know Eyepoint will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Eyepoint Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.82) | Revenue Per Share 1.183 | Quarterly Revenue Growth 0.332 | Return On Assets (0.17) | Return On Equity (0.39) |
The market value of Eyepoint Pharmaceuticals is measured differently than its book value, which is the value of Eyepoint that is recorded on the company's balance sheet. Investors also form their own opinion of Eyepoint Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Eyepoint Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Eyepoint Pharmaceuticals' market value can be influenced by many factors that don't directly affect Eyepoint Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Eyepoint Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Eyepoint Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Eyepoint Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.